文献速递神经核医学肿瘤 PET/CT

18F-Fluciclovine PET/CT在疑似复发高级别胶质瘤中的应用

18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma.
PubMed 文献 · Clin Nucl Med · 2019-01-01

该回顾性研究纳入21例疑似复发高级别胶质瘤患者,评估18F-Fluciclovine PET/CT的摄取情况。所有患者均符合参考标准(组织病理学复发10例,临床及MRI进展11例)。病灶平均SUVmax为8.3±5.3,正常脑组织为0.34±0.13,中位病灶/本底比值为21.6。4例患者中PET/CT检出MRI未报告的小卫星肿瘤。

要点

  • 18F-Fluciclovine在复发高级别胶质瘤中摄取高,病灶/本底比值中位达21.6。
  • 4例患者PET/CT检出MRI未报告的小卫星肿瘤。
  • 因未纳入治疗相关改变患者,无法确定其鉴别复发与假性进展/放射性坏死的能力。

核心结论

  • 18F-Fluciclovine在临床和/或组织病理学证实的复发高级别胶质瘤中摄取高,高于其他氨基酸PET示踪剂报告的摄取。
  • 高肿瘤摄取和高示踪剂对比度使4例患者中检出MRI未报告、直径低于通常报道的PET空间分辨率的小卫星肿瘤。
  • 因未纳入确认的治疗相关改变患者,目前无法确定18F-Fluciclovine PET鉴别复发高级别胶质瘤与治疗相关改变(如假性进展和放射性坏死)的能力。

研究设计与样本

  • 回顾性研究,纳入21例疑似复发高级别胶质瘤患者。
  • 参考标准:有组织病理学结果时采用组织病理学解释;无组织病理学或再活检未显示恶性迹象时,采用包括MRI和临床结局的临床随访作为参考标准。

主要发现

  • 所有21例患者均符合参考标准:组织病理学证实高级别胶质瘤复发10例,临床及随访MRI显示肿瘤生长对应原发肿瘤部位的疾病进展11例。
  • PET/CT至死亡的中位时间为5个月(范围1-20个月);原发诊断至死亡的中位时间为14.5个月(范围6至>400个月)。
  • 病灶平均SUVmax为8.3±5.3(标准差),正常脑组织为0.34±0.13。
  • 中位病灶/本底比值为21.6(范围3.1-84.4)。
  • 4例患者中18F-Fluciclovine PET/CT检出MRI未报告的小卫星肿瘤。

临床怎么用

  • 18F-Fluciclovine PET/CT在疑似复发高级别胶质瘤中显示高肿瘤摄取和高对比度,可辅助检出MRI未报告的小卫星肿瘤。
  • 目前尚不能用于鉴别复发高级别胶质瘤与治疗相关改变(如假性进展和放射性坏死),因研究未纳入此类患者。

局限性

  • 回顾性研究,样本量较小(21例)。
  • 未纳入确认的治疗相关改变患者,无法评估鉴别复发与治疗相关改变的能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To retrospectively investigate the uptake of F-fluciclovine on PET/CT in patients with suspected recurrent high-grade glioma (HGG). METHODS: Twenty-one patients were included. The standard of truth was histopathologic interpretation if available. When histopathology was not available or rebiopsy did not show signs of malignancy, clinical follow-up including MRI and clinical outcome was considered the standard of truth. RESULTS: All 21 patients met the reference standard of either histopathologic proof of HGG recurrence (n = 10) or disease progression clinically and with tumor growth corresponding to the primary tumor sites on follow-up MRI (n = 11). Median time from PET/CT to death was 5 months (range, 1-20 months). Median time from primary diagnosis to death was 14.5 months (range, 6 to >400). Average SUVmax of the lesions was 8.3 ± 5.3 (SD) and 0.34 ± 0.13 for normal brain tissue. Median lesion-to-background ratio was 21.6 (range, 3.1-84.4). In 4 patients, F-fluciclovine PET/CT detected small satellite tumors that had not been reported on MR. CONCLUSIONS: The uptake of F-fluciclovine in clinically and/or histopathologically confirmed recurrent HGG is high compared with the uptake reported for other amino acid PET tracers. Because of the high tumor uptake and thus high tracer contrast, small satellite tumors with a diameter below usual reported PET spatial resolution and not reported on MRI were detected in 4 patients. As no patients with confirmed treatment-related changes were included, we cannot as of yet ascertain the ability of F-fluciclovine PET to discriminate between recurrent HGG and treatment-related changes, for example, pseudoprogression and radionecrosis.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bogsrud TV, Londalen A, Brandal P, et al. 18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma. Clin Nucl Med. 2019. PMID: 31274605. doi:10.1097/RLU.0000000000002641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。